No Decreased Survival in Blacks With AML Compared With Whites No Decreased Survival in Blacks With AML Compared With Whites

Although blacks with acute myeloid leukemia were more likely to have evidence of abnormal kidney function, the excess of this comorbidity didn't affect overall survival, compared with whites.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Related Links:

No abstract available
Source: Oncology Times - Category: Cancer & Oncology Tags: News Source Type: research
ConclusionThese results highlight an anti-cancer activity of prazosin on AML by inhibiting the PI3K/Akt/mTOR pathway and targeting TNS1.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
We present a 61-year-old male withFLT3-mutated acute myeloid leukemia treated with midostaurin who developed acute kidney injury requiring hemodialysis and pulmonary renal syndrome. Antibodies to proteinase-3, myeloperoxidase, and glomerular basement membrane were negative. Renal biopsy confirmed acute pauci-immune focal necrotizing glomerulonephritis (GN) with fibrin crescents indicating rapidly progressing glomerulonephritis. He improved with pulse methylprednisolone, intravenous cyclophosphamide, and plasma exchange with resolution of hemoptysis. This case highlights the importance of prompt renal biopsy to guide early ...
Source: CEN Case Reports - Category: Urology & Nephrology Source Type: research
Publication date: Available online 16 January 2020Source: Leukemia Research ReportsAuthor(s): Toshie Ogasawara, Kiyotaka Kawauchi, Takuya Ono, Kotaro Shide, Kazuya Shimoda, Naoki Mori, Hiroshi SakuraAbstractEssential thrombocythemia (ET) is an indolent myeloproliferative neoplasm (MPN) with a transformation to acute myeloid leukemia in
Source: Leukemia Research Reports - Category: Hematology Source Type: research
(Karolinska Institutet) A common and inexpensive drug may be used to counteract treatment resistance in patients with acute myeloid leukemia (AML), one of the most common forms of blood cancer. This is the conclusion of a study in mice and human blood cells performed at Karolinska Institutet and SciLifeLab and published in the medical journal EMBO Molecular Medicine. The researchers will now launch a clinical study to test the new combination treatment in patients.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Conditions:   Acute Myelogenous Leukemia (AML) Due to Therapy;   Acute Myeloid Leukemia With Myelodysplasia-Related Changes Interventions:   Drug: Glasdegib;   Drug: CPX-351 Sponsors:   University of California, Irvine;   Jazz Pharmaceuticals;   Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
We report that the acute myeloid leukemia (AML)-associated CBFβ-SMMHC fusion oncoprotein physically interacts with the PRC1 complex and that these factors co-localize across the AML genome in an apparently PRC2-independent manner. Depletion of CBFβ-SMMHC caused substantial increases in genome-wide PRC1 binding and marked changes in the association between PRC1 and the CBF DNA-binding subunit RUNX1. PRC1 was more likely to be associated with actively transcribed genes in CBFβ-SMMHC-expressing cells. CBFβ-SMMHC depletion had heterogeneous effects on gene expression, including significant reductions in tra...
Source: Cell Reports - Category: Cytology Source Type: research
andra Biffi There is still little research on psychological wellbeing, life satisfaction and reported problems in preadolescents and adolescents under therapy for leukaemia, and also little research comparing them with their healthy peers. The present study aimed to analyse the life satisfaction, hope, psychological wellbeing and reported problems’ intensity in 60 patients aged 8–18 during the first year of therapy, to identify those more at risk and to compare their reports with matched healthy peers. A battery of self-reported questionnaires was administered during hospitalisation or day hospital ...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
Publication date: Available online 15 January 2020Source: Biochimica et Biophysica Acta (BBA) - Molecular Cell ResearchAuthor(s): Stefano Ratti, Sara Mongiorgi, Isabella Rusciano, Lucia Manzoli, Matilde Y. FolloAbstractGSK-3 and PLCbeta enzymes are responsible for the regulation of several signalling pathways related to many cellular functions. In hematopoietic cells, GSK-3 deficiency is correlated with an MDS-like phenotype and with leukemogenesis, showing a prognostic potential in AML cells. GSK-3 interacts with Wnt or MAPK signalling, but it is also linked to PI3K/Akt/mTOR pathways to regulate cell proliferation and apo...
Source: Biochimica et Biophysica Acta (BBA) Molecular Cell Research - Category: Molecular Biology Source Type: research
Condition:   Leukemia, Myeloid, Acute Interventions:   Drug: azacitidine;   Drug: venetoclax;   Drug: glasdegib Sponsor:   Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Health | Hematology | Leukemia | Urology & Nephrology